Company Dossier · Health Care
Boston Scientific
- S&P 500
- Russell 1000
What Boston Scientific is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $21.0 billion, up 14% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $3.63 billion, up 4.0% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.90 billion, up 12% from a year earlier.SEC EDGAR filings (XBRL)
- Long-term debt issued in the fiscal year to December 31, 2025: $1.56 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 29, 2026): sentiment -0.40 on a −1 to +1 scale (negative), confidence 0.60 of 1.Palanor Discourse
- Guidance in the last 90 days: 0 outlook figures raised, 3 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 17, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net buyers in Q3 2026: $9.5 million on the open market.SEC Form 4
- 1,489 institutional managers reported a position at June 30, 2026 (−195 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 36 (40 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 1 — latest OSHA inspection, Jan 5, 2026 →
Company Posture
How Company Posture is measured →What Boston Scientific is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Hedging
Expanding ↔ Retrenching
Steady
- Capital spending64th pct
- Debt raised14th pct
- Buybacks vs capex—
- Hiring filings29th pct
- Deals and private raises49th pct
- Patent publications26th pct
Confident ↔ Hedging
Hedging
- Call sentiment5th pct
- Call confidence10th pct
- Guidance changes6th pct
- Risk factors added67th pct
- Insider open-market trades95th pct
- − Call sentiment
- − Guidance changes
- − Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver71st pct
- Stress filings97th pct
Credit
How these are built →Boston Scientific's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$12.6B
- Due within a year $1.7B
- Longer term $10.9B
- Default point $7.2B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Boston Scientific, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralMedical device maker Boston Scientific says a cyberattack is causing a ‘global disruption’ to its operations
The company won't say if medical devices are affected or if any customer data was exfiltrated.
TechCrunch · Aug 26, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (LIBERTY PARTNERS GROUP, LLC)third_quarter 2026
- Oct 20, 2026LobbyingLobbying report (FARRAGUT PARTNERS LLP)third_quarter 2026 · $0.0 million
- Oct 20, 2026LobbyingLobbying report (ALSTON & BIRD LLP)third_quarter 2026 · $0.1 million
- Oct 20, 2026PatentPatent granted: BLOOD PUMP SHAFT BEARINGUS 12766309
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 16, 2026LobbyingLobbying report (HOLLIER & ASSOCIATES)third_quarter 2026 · $0.1 million
- Oct 16, 2026LobbyingLobbying report (BRICK STREET STRATEGY)third_quarter 2026 · $0.0 million
- Oct 15, 2026LobbyingLobbying report (BOSTON SCIENTIFIC CORPORATION)third_quarter 2026 · $0.6 million
- Oct 7, 20268-KDirector or officer changeItem 5.02
- Sep 23, 20268-KDirector or officer changeItem 5.02
- Sep 8, 20268-KCybersecurity incidentItem 1.05
- Jul 27, 20268-KExit or restructuring costsItem 2.05
- Jul 21, 2026LobbyingLobbying report (HOLLIER & ASSOCIATES)second_quarter 2026 · $0.1 million
- Jul 21, 2026LobbyingLobbying report (LIBERTY PARTNERS GROUP, LLC)second_quarter 2026
- Jun 30, 2026Private creditLoans held by business development companies (Boston Scientific Corp.)$0.9 million at cost
- May 5, 20268-KShareholder vote resultsItem 5.07
- Feb 26, 20268-KMaterial agreement signedItem 1.01
- Feb 26, 20268-KMaterial agreement terminatedItem 1.02
- Feb 23, 20268-KDirector or officer changeItem 5.02
- Feb 17, 202610-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 5, 20268-KDirector or officer changeItem 5.02
- Jan 15, 20268-KMaterial agreement signedItem 1.01
- Jan 5, 2026Risk event
- Nov 19, 20258-KDirector or officer changeItem 5.02
- Oct 23, 20258-KDirector or officer changeItem 5.02
- Sep 4, 20258-KDirector or officer changeItem 5.02
- May 6, 20258-KShareholder vote resultsItem 5.07
- Apr 23, 20258-KDirector or officer changeItem 5.02
- Feb 26, 20258-KMaterial agreement signedItem 1.01
- Feb 18, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 12, 20258-KDirector or officer changeItem 5.02
- Nov 22, 20248-KDirector or officer changeItem 5.02
- Feb 20, 202410-KAnnual report (10-K)0 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| GE HealthCare GEHC | $21.0B | — | Mar 31, 2026 |
| Becton Dickinson BDX | $22.5B | $2.7B | Jun 30, 2026 |
| Stryker Corporation SYK | $25.8B | $4.7B | Jun 30, 2026 |
| Medtronic MDT | $37.5B | $6.1B | Jul 31, 2026 |
| Baxter International BAX | $11.5B | — | Jun 30, 2026 |
| Intuitive Surgical ISRG | $11.0B | $3.2B | Jun 30, 2026 |
| Zimmer Biomet ZBH | $8.5B | $1.5B | Jun 30, 2026 |
| Edwards Lifesciences EW | $6.5B | $1.4B | Jun 30, 2026 |